Hepatitis D Clinical Trial
Official title:
An Open-label, Randomized Study to Compare the Efficacy and Safety of P1101 Plus Tenofovir Alafenamide With or Without Ursodeoxycholic Acid in Patients With Chronic Hepatitis B and Hepatitis D Virus Co-Infection
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
There will be 2 treatment groups in this study, 15 subjects per group as follows: Group 1: TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks. Group 2: Ursodeoxycholic Acid (UDCA)* 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks. Both groups will have a post-treatment follow-up of 24 weeks. *: Dose of Ursodeoxycholic Acid (UDCA) will be determined by weight at Day 1 (TW0) in 2-4 divided doses. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02044055 -
Mother-to-child Hepatitis D Transmission
|
N/A | |
| Completed |
NCT02375906 -
The Hepatitis Delta International Network
|
||
| Not yet recruiting |
NCT05394623 -
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
|
||
| Recruiting |
NCT04863703 -
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
|
||
| Recruiting |
NCT06397859 -
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
|
||
| Recruiting |
NCT00001971 -
Evaluation of Patients With Liver Disease
|
||
| Recruiting |
NCT06264583 -
HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
|
||
| Recruiting |
NCT05928000 -
HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
|
||
| Recruiting |
NCT06122285 -
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
|
||
| Terminated |
NCT04847440 -
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
|
Phase 2 | |
| Recruiting |
NCT05936073 -
DELTA DESCRIBE: the French Collaborative Project
|
||
| Completed |
NCT00932971 -
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
|
Phase 2 | |
| Completed |
NCT06360484 -
Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
|
||
| Completed |
NCT02511431 -
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
|
Phase 2 | |
| Not yet recruiting |
NCT05451082 -
Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
|
||
| Recruiting |
NCT05903742 -
Standardising Care for Hepatitis Delta in the Netherlands
|
||
| Not yet recruiting |
NCT03362866 -
Epidemiology of Hepatitis B, C and Delta in Reunion Island
|
||
| Terminated |
NCT01316185 -
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
|
Phase 1 | |
| Recruiting |
NCT05264272 -
Disease Loads and Status of Treatment
|
||
| Completed |
NCT05002907 -
Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
|